Citi Reiterates Sell Rating on Ionis Pharmaceuticals (IONS), 'Limited Detail Keeps Us Weary on Competitive Profile', PT $26
Tweet Send to a Friend
Citi analyst David Lebowitz reiterated a Sell rating and $26.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).The analyst comments "Ionis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
